Sulfonamide derivatives
AssigneeEli Lilly and Company
InventorsPaul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
Life of this patent
Estimating the term…
Abstract
The present invention relates to a compound of formula (Ia) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.
Claims15
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
A composition comprising a compound of the formula:
- or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, diluent or excipient.
A method of potentiating glutamate receptor function in a patient, which comprises administering to said patient an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A method of treating depression in a patient comprising administering to said patient an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A method of treating schizophrenia in a patient comprising administering to said patient an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A method of treating cognitive disorders in a patient comprising administering to said patient an effective amount of a compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A process for the preparation of a compound of formula Ia:
- comprising, nitrating a sulfonamide (5):
- to provide a p-nitro derivative (6):
- hydrogenating the p-nitro derivative (6) to provide a p-amino derivative (7):
- treating the p-amino derivative (7) with a suitable acid, then treating with a suitable base, and then treating with 3,5difluorobenzoyl chloride.
An article of manufacture comprising packaging material and a compound of formula:
- or a pharmaceutically acceptable salt thereof contained within said packaging material, wherein said packaging material comprises a label which indicates that said compound can be used for treating at least one of the following;
- Alzheimer's disease, schizophrenia, cognitive deficits associated with schizophrenia, depression, and cognitive disorders.
An article of manufacture according to claiam 9 wherein said label indicates that said compound can be used for treating Alzheimer's disease.
A method of treating Parkinson's disease in a patient comprising administering to said patient an effective amount of a compound of the formula:
A method of treating Alzheimer's disease in a patient comprising administering to said patient an effective amount of a compound of the formula:
Dependencies are inferred from the claim text.